imt-2021-0135: - Supplementary Material: Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer- a meta-analysis

<div> <table> <tr> <td> <p>Supplementary Figure S2: Progression-free survival in patients who received etoposide and non-etoposide (carboplatin-paclitaxel) as the standard chemotherapy</p><p><br></p><p>Aims: This meta-analysis investigated the clinical benefits of chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). <br> Methods/Results: Seven randomized controlled trials with a total of 2,862 patients were analyzed. Compared with chemotherapy alone, chemo-immunotherapy provided a better progression-free survial (PFS) with a hazard ratio (HR) of 0.81; P<0.00001, and overall survival (OS) (HR, 0.82; P<0.0001). However, the incidence of treatment related adverse effects (TRAEs) was significantly increased. Subgroup analyses showed that a good performance status, cisplatin-based chemotherapy, without brain metastases, and non-Asian populations were associated with greater benefits in OS from chemo-immunotherapy. <br> Conclusion: Chemo-immunotherapy demonstrated better PFS and OS compared to chemotherapy alone as first-line treatment in ES-SCLC, but additional TRAEs should be closely monitored.<br></p> </td> </tr> </table> </div>